Sumit Kumar

About

Kumar is a medicinal-drug discovery scientist with expertise spanning synthetic chemistry, early hit discovery, and lead optimization. After earning his Ph.D. in Medicinal Chemistry (2019), he gained international experience across India, South Korea, and South Africa, contributing to highly collaborative and multi-disciplinary industrial/academic projects in infectious diseases and nanomedicine.
He is currently a Lead Medicinal Scientist (Biomedicine) at the University of Bergen, where he leads a multidisciplinary NeuroConvergence project focused on advancing therapeutic strategies in neuroscience through integrated chemical, biological, and computational approaches.

Employment

• University of Bergen Lead Medicinal Scientist
  2025 - Present
• H3D Drug Discovery and Development Centre, University of Cape Town Post Doctoral Researcher
  2021 - 2024
• Seoul National University Post Doctoral Researcher
  2020 - 2021
• Sphaera Pharma (India) Research Associate
  2019 - 2020

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (20)

• Discovery of Small-Molecule Inhibitors of the KCNQ1/Kv7.1 Potassium Channel with Virtual Screening and Functional Validation in Electrophysiological Assays and KCNQ1-Knockout Neural Stem Cells
  ACS Chemical Neuroscience 2026 DOI: 10.1021/acschemneuro.6c00197
  +Save
• Unlocking Opportunities for Mycobacterium leprae and Mycobacterium ulcerans
  ACS Infectious Diseases 2024 DOI: 10.1021/acsinfecdis.3c00371
  +Save
• Recent developments of imidazo[1,2-a]pyridine analogues as antituberculosis agents
  RSC Medicinal Chemistry 2023 DOI: 10.1039/d3md00019b
  +Save
• 7‐chloroquinoline‐chalcone/‐pyrazoline conjugates: Synthesis, antimycobacterial and cytotoxic activities
  Journal of Heterocyclic Chemistry 2022 DOI: 10.1002/jhet.4486
  +Save
• 1H-1,2,3‐triazole embedded Isatin‐Benzaldehyde‐bis(heteronuclearhydrazones): design, synthesis, antimycobacterial, and cytotoxic evaluation
  Chemical Biology & Drug Design 2022 DOI: 10.1111/cbdd.13984
  +Save
• Biological and Biochemical Evaluation of Isatin-Isoniazid Hybrids as Bactericidal Candidates against Mycobacterium tuberculosis
  Antimicrobial Agents and Chemotherapy 2021 DOI: 10.1128/aac.00011-21
  +Save
• Synthesis and antiplasmodial evaluation of 1H-1,2,3-triazole grafted 4-aminoquinoline-benzoxaborole hybrids and benzoxaborole analogues
  Bioorganic Chemistry 2021 DOI: 10.1016/j.bioorg.2021.104733
  +Save
• Recent accomplishments on the synthetic/biological facets of pharmacologically active 1H-1,2,3-triazoles
  European Journal of Medicinal Chemistry 2021 DOI: 10.1016/j.ejmech.2020.113069
  +Save
• Design, synthesis, heme binding and density functional theory studies of isoindoline-dione-4-aminoquinolines as potential antiplasmodials
  Future Medicinal Chemistry 2020 DOI: 10.4155/fmc-2019-0260
  +Save
• Amalgamating Isatin/Indole/Nitroimidazole with 7‐chloroquinolines via azide‐alkyne cycloaddition: Synthesis, anti‐plasmodial, and cytotoxic evaluation
  Chemical Biology & Drug Design 2020 DOI: 10.1111/cbdd.13738
  +Save